Who
David Matthew Stark
Director
Company insider
Files Form 4 as: Director, Assertio Holdings; Exec. VP Chief Legal Officer, Teva Pharmaceutical Industries.
In numbers
- Trades disclosed
- 98
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $4.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 9 Feb 2018
- Last trade
- 16 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 16 Jun 2026 | Assertio HoldingsBiotechnology | SEC FORM 4 Code U | —11,420 at $0.00 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdings | SEC FORM 4 Code U | —11,420 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | Assertio HoldingsBiotechnology | SEC FORM 4 Code A | —4,851 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | Assertio Holdings | SEC FORM 4 Code A | —4,851 at $0.00 | filing |
| 10 Nov 2025filed 12 Nov 2025 | Assertio Holdings | SEC FORM 4 Sold | $6,8098,959 at $0.76 | filing |
| 7 May 2025filed 9 May 2025 | Assertio Holdingsoption or derivative | SEC FORM 4 Code A | —81,225 at $0.00 | filing |
| 7 May 2025filed 9 May 2025 | Assertio Holdings | SEC FORM 4 Code A | —53,750 at $0.00 | filing |
| 7 Nov 2024filed 12 Nov 2024 | Assertio Holdingsoption or derivative | SEC FORM 4 Code A | —81,225 at $0.00 | filing |
| 7 Nov 2024filed 12 Nov 2024 | Assertio Holdings | SEC FORM 4 Code A | —53,750 at $0.00 | filing |
| 7 Mar 2023filed 8 Mar 2023 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $467K49,475 at $9.43 | filing |
| 6 Mar 2023filed 8 Mar 2023 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $164K16,491 at $9.93 | filing |
| 5 Mar 2023filed 7 Mar 2023 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —20,199 at $0.00 | filing |
| 5 Mar 2023filed 7 Mar 2023 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —20,199 | filing |
| 4 Mar 2023filed 7 Mar 2023 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —13,931 at $0.00 | filing |
| 4 Mar 2023filed 7 Mar 2023 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —31,836 at $0.00 | filing |
| 4 Mar 2023filed 7 Mar 2023 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —13,931 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 16 Oct 2026Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $50.00TEVA · dailypolitical.com · 15 Oct 2026Analyzing Astrazeneca (NYSE:AZN) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name David Matthew Stark; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.